Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa

  • Mayer Srour
  • Giuseppe Querques
  • Nicolas Leveziel
  • Jennyfer Zerbib
  • Julien Tilleul
  • Elise Boulanger-Scemama
  • Eric H. Souied
Retinal Disorders

Abstract

Background

To evaluate the anatomical and functional outcomes of intravitreal dexamethasone implant in patients with macular edema (ME) secondary to retinitis pigmentosa (RP).

Methods

Three patients (four eyes), aged 24 to 46 years, presented with refractory ME secondary to RP. Intravitreal dexamethasone implant (Ozurdex) was administered to treat ME. The anatomical (central macular thickness [CMT]) and functional (best-corrected visual acuity [BCVA]) outcomes as well as adverse events were recorded.

Results

All patients completed 6 months follow-up. After intravitreal Ozurdex all patients showed regression of ME. At baseline, mean CMT was 443 ± 185 μm (range 213–619 μm); ME improved to 234 ± 68 μm (range 142–307 μm) at 1 month, to 332 ± 177 μm (range 139–513 μm) at 3 msonth, and to 305 ± 124 μm (range 144–447 μm) at 6 months. Recurrent ME was recorded in 2 patients (both patients at 3 months from intravitreal dexamethasone implant). Retreatment with intravitreal Ozurdex was performed in two patients. Mean BCVA improved form 20/160 (range 20/50–20/200) (baseline) to 20/100 (range 20/40–20/125) at 1 month, to ∼20/125 (range 20/100–20/200) at 3 months, and to ∼ 20/125 (range 20/100–20/160) at 6 months. No serious ocular and systemic adverse events were observed during the study period.

Conclusions

Intravitreal dexamethasone implant provides anatomic and functional improvements and may represent a valuable treatment option for patients with ME secondary to RP.

Keywords

Dexamethasone implant Macular edema Multifocal optical coherence tomography Ozurdex Retinitis pigmentosa 

Notes

Conflict of interest

The authors have no proprietary interest in the materials used in this study.

Financial support

None

References

  1. 1.
    Newsome DA, Blacharski PA (1987) Grid photocoagulation for macular oedema in patients with retinitis pigmentosa. Am J Ophthalmol 103:161–166PubMedGoogle Scholar
  2. 2.
    García-Arumí J, Martinez V, Sararols L, Corcostegui B (2003) Vitreoretinal surgery for cystoid macular edema associated with retinitis pigmentosa. Ophthalmology 110:1164–1169PubMedCrossRefGoogle Scholar
  3. 3.
    Cox SN, Hay E, Bird AC (1988) Treatment of chronic macular oedema with acetazola- mide. Arch Ophthalmol 106:1190–1195PubMedCrossRefGoogle Scholar
  4. 4.
    Saraiva VS, Sallum JMF, Farah ME (2003) Treatment of cystoid macular oedema related to retinitis pigmentosa with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 34:398–400PubMedGoogle Scholar
  5. 5.
    Scorolli L, Morara M, Meduri A, Reggiani LB, Ferreri G, Scalinci SZ, Meduri RA (2007) Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 125:759–764PubMedCrossRefGoogle Scholar
  6. 6.
    Bressler NM, Schachat AP (2010) Management of macular edema from retinal vein occlusions you can never have too many choices. Ophthalmology 117:1061–1063PubMedCrossRefGoogle Scholar
  7. 7.
    Goldfien A (1995) Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG (ed) Basic and Clinical Pharmacology, 6th edn. Prentice Hall International, London, pp 592–607Google Scholar
  8. 8.
    Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM, Dexamethasone DDS Phase II Study Group (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317PubMedCrossRefGoogle Scholar
  9. 9.
    Haller J, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM, OZURDEX GENEVA Study Group (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146PubMedCrossRefGoogle Scholar
  10. 10.
    Heckenlively JR, Jordan BL, Aptsiauri N (1999) Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127:565–573PubMedCrossRefGoogle Scholar
  11. 11.
    Giusti C, Forte R, Vingolo EM (2002) Deflazacort treatment of cystoid macular edema in patients affected by Retinitis Pigmentosa: a pilot study. Eur Rev Med Pharmacol Sci 6:1–8PubMedGoogle Scholar
  12. 12.
    Ozdemir H, Karacorlu M, Karacorlu S (2005) Intravitreal triamcinolone acetonide for treatment of cystoid macular oedema in patients with retinitis pigmentosa. Acta Ophthalmol Scand 83:248–251PubMedCrossRefGoogle Scholar
  13. 13.
    SCORE Study Research Group (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol 127:1115–1128CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Mayer Srour
    • 1
  • Giuseppe Querques
    • 1
    • 2
    • 3
  • Nicolas Leveziel
    • 1
  • Jennyfer Zerbib
    • 1
  • Julien Tilleul
    • 1
  • Elise Boulanger-Scemama
    • 1
  • Eric H. Souied
    • 1
  1. 1.Department of OphthalmologyCentre Hospitalier Intercommunal de Creteil University Paris Est CreteilCreteilFrance
  2. 2.Department of OphthalmologyHospital San Raffaele, University Vita Salute San RaffaeleMilanItaly
  3. 3.Department of OphthalmologyCentre Hospitalier Intercommunal de CreteilCreteilFrance

Personalised recommendations